-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on CytomX Therapeutics, Raises Price Target to $16

Benzinga·03/19/2026 14:25:20
Listen to the news
Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $10 to $16.